Literature DB >> 21392606

Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women.

Ida J Hatoum1, Nancy R Cook, Jeanenne J Nelson, Kathryn M Rexrode, Eric B Rimm.   

Abstract

BACKGROUND: This study sought to determine the relation between and discriminative capability of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and coronary heart disease (CHD) in a large population of disease-free women.
METHODS: Among participants of the Nurses' Health Study who provided a blood sample, there were 421 cases of incident myocardial infarction during 14 years of follow-up. Controls were matched to cases 2:1 using risk set sampling based on age, smoking, and blood draw date.
RESULTS: After conditioning on the matching factors, Lp-PLA(2) activity was significantly associated with myocardial infarction (relative risk [RR] 2.86 for extreme quartiles, 95% CI 1.98-4.12). Upon additional adjustment for lipid, inflammatory, and clinical risk factors, the RR remained statistically significant (RR 1.75, 95% CI 1.09-2.84). The discriminative capability of Lp-PLA(2) was assessed by comparing the area below the receiver operating characteristic curves for models with and without Lp-PLA(2) and by calculating the net reclassification improvement index. The addition of Lp-PLA(2) activity to a multivariable-adjusted model increased the receiver operating characteristic curves from 0.720 to 0.733 and significantly improved the net reclassification improvement index (P = .004).
CONCLUSIONS: Levels of Lp-PLA(2) activity were significantly associated with incident CHD among women. In addition, Lp-PLA(2) activity added significantly to CHD risk discrimination.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21392606      PMCID: PMC3073524          DOI: 10.1016/j.ahj.2010.11.007

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  26 in total

1.  Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.

Authors:  Emmanouil S Brilakis; Joseph P McConnell; Ryan J Lennon; Ahmad A Elesber; Jeffrey G Meyer; Peter B Berger
Journal:  Eur Heart J       Date:  2004-11-29       Impact factor: 29.983

2.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease.

Authors:  M J Caslake; C J Packard; K E Suckling; S D Holmes; P Chamberlain; C H Macphee
Journal:  Atherosclerosis       Date:  2000-06       Impact factor: 5.162

3.  Test of the National Death Index.

Authors:  M J Stampfer; W C Willett; F E Speizer; D C Dysert; R Lipnick; B Rosner; C H Hennekens
Journal:  Am J Epidemiol       Date:  1984-05       Impact factor: 4.897

4.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

Review 5.  Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.

Authors:  Andrew Zalewski; Colin Macphee
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

6.  Inflammatory markers and the risk of coronary heart disease in men and women.

Authors:  Jennifer K Pai; Tobias Pischon; Jing Ma; JoAnn E Manson; Susan E Hankinson; Kaumudi Joshipura; Gary C Curhan; Nader Rifai; Carolyn C Cannuscio; Meir J Stampfer; Eric B Rimm
Journal:  N Engl J Med       Date:  2004-12-16       Impact factor: 91.245

7.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.

Authors:  Irene Gazi; Evangelia S Lourida; Theodosios Filippatos; Vasilis Tsimihodimos; Moses Elisaf; Alexandros D Tselepis
Journal:  Clin Chem       Date:  2005-10-13       Impact factor: 8.327

8.  Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.

Authors:  Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

9.  Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.

Authors:  Alexander Thompson; Pei Gao; Lia Orfei; Sarah Watson; Emanuele Di Angelantonio; Stephen Kaptoge; Christie Ballantyne; Christopher P Cannon; Michael Criqui; Mary Cushman; Albert Hofman; Chris Packard; Simon G Thompson; Rory Collins; John Danesh
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

10.  Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.

Authors:  Wolfgang Koenig; Natalie Khuseyinova; Hannelore Löwel; Gerlinde Trischler; Christa Meisinger
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

View more
  8 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Determination of phospholipase activity of PAF acetylhydrolase.

Authors:  Diana M Stafforini; Thomas M McIntyre
Journal:  Free Radic Biol Med       Date:  2012-05-29       Impact factor: 7.376

3.  A novel fatty acid lipophilic index and risk of CHD in US men: the health professionals follow-up study.

Authors:  Hongyu Wu; Eric L Ding; Estefanía T Toledo; Hannia Campos; Ana Baylin; Frank B Hu; Qi Sun
Journal:  Br J Nutr       Date:  2013-01-08       Impact factor: 3.718

Review 4.  Biomarkers and cardiovascular risk assessment for primary prevention: an update.

Authors:  Lauren G Gilstrap; Thomas J Wang
Journal:  Clin Chem       Date:  2011-11-28       Impact factor: 8.327

5.  Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

Authors:  Jing Liu; Yuling Hong; Yue Qi; Fan Zhao; Dong Zhao
Journal:  N Am J Med Sci (Boston)       Date:  2011-10

6.  Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways.

Authors:  Xiaolei Han; Tiedong Wang; Jifeng Zhang; Xingxing Liu; Zhuang Li; Gangqi Wang; Qi Song; Daxin Pang; Hongsheng Ouyang; Xiaochun Tang
Journal:  Biol Open       Date:  2015-04-02       Impact factor: 2.422

Review 7.  Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?

Authors:  Anwar Santoso; Teuku Heriansyah; Mohammad S Rohman
Journal:  Curr Cardiol Rev       Date:  2020

Review 8.  Novel cardiovascular risk markers in women with ischaemic heart disease.

Authors:  Dana Pop; Alexandra Dădârlat; D Zdrenghea
Journal:  Cardiovasc J Afr       Date:  2014 May-Jun       Impact factor: 1.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.